drugset / Trial / NCT03425799

Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery

NCT03425799

Phase 3 Terminated 5 enrolled Exela Pharma Sciences, LLC.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to see if Tranexamic Acid can safely reduce bleeding in people undergoing spinal fusion surgery.

Timeline

Start
2018-10-17
Primary completion
2019-10-23
Completion
2020-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 3 mg/kg Intravenous

Indications

No indication recorded.